Drugs / ALA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03024060 | Mar → Sep 2017 | actinic keratosis | DUSA Pharmaceuticals, Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03024060 ↗ |
| Route | Topical | “20% ALA applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light” NCT03024060 ↗ |